Clinical Trial Update: HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for patritumab deruxtecan in metastatic or EGFR-mutated non-small cell lung cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-04-02